BERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the Citi 2025 Biopharma Back to School Conference on September 3, 2025 at 2:30 PM EDT. For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Carib ...

Company Overview - Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing transformative therapies for patients with severe diseases [3] - The company's genome-editing platform utilizes Cas12a chRDNA technology, which offers superior precision for developing cell therapies [3] - Caribou is concentrating on CB-010 and CB-011 as off-the-shelf CAR-T cell therapies aimed at providing broad access and rapid treatment for patients with hematologic malignancies [3] Upcoming Events - Rachel Haurwitz, PhD, the president and CEO of Caribou, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4 at 9:20 AM EDT [1] - A link to the webcast of the event will be available on Caribou's website, and the webcasts will remain accessible for at least 30 days post-event [2]

Company Overview - Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing transformative therapies for patients with severe diseases [3] - The company's genome-editing platform utilizes Cas12a chRDNA technology, which offers superior precision for developing cell therapies aimed at improving activity against diseases [3] Product Focus - Caribou is concentrating on two off-the-shelf CAR-T cell therapies, CB-010 and CB-011, which have the potential to provide broad access and rapid treatment for patients suffering from hematologic malignancies [3] Upcoming Events - Rachel Haurwitz, PhD, the president and CEO of Caribou, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13th at 2:35 PM PDT [1] - Webcasts of the event will be available on Caribou's website for at least 30 days following the event [2]

Core Insights - Caribou Biosciences is strategically prioritizing its lead oncology programs, CB-010 and CB-011, while implementing workforce and cost reduction initiatives to extend its cash runway into H2 2027 [1][13] - The company plans to disclose robust clinical datasets for CB-010 and CB-011 in H2 2025, which are expected to demonstrate efficacy in treating hematologic malignancies [2][14] Pipeline Prioritization - Caribou is focusing resources on CB-010 and CB-011, discontinuing the GALLOP Phase 1 trial for lupus and the AMpLify Phase 1 trial for acute myeloid leukemia [5][7] - The workforce reduction is approximately 32%, with expected cash savings of $2.5 to $3.5 million from these strategic decisions [13] Clinical Programs - CB-010 is an allogeneic anti-CD19 CAR-T cell therapy for B cell non-Hodgkin lymphoma, with data expected to show outcomes comparable to approved autologous CAR-T therapies [6][10] - CB-011 is an allogeneic anti-BCMA CAR-T cell therapy for multiple myeloma, with ongoing dose escalation trials showing encouraging efficacy [4][11] Financial Position - As of March 31, 2025, Caribou expects to report $212.5 million in cash, cash equivalents, and marketable securities [8] - The strategic changes are anticipated to extend the company's cash runway by one year, allowing operations to continue into H2 2027 [13] Upcoming Milestones - In H2 2025, Caribou plans to present data from the ANTLER Phase 1 trial for CB-010, including safety and efficacy data from a 20-patient cohort [14] - For CB-011, the company will present dose escalation data and recommended doses for expansion from the ongoing CaMMouflage Phase 1 trial [14]